Bionor Pharma completes private placement after Solon Eindom buy

Norwegian Bionor Pharma ASA announced the acquisition of Solon Eiendom AS for a total consideration of approximately NOK 1,000 million ($116.5M)to be settled by issuing 6,666,666,666 new shares.

The Private Placement was completed on Wednesday and a total of 2,000,000,000 shares were agreed to be sold. The Private Placement attracted significant interest from high quality investors and was more than 5 times oversubscribed. Arctic Securities AS, DNB Markets, a part of DNB Bank ASA, and SpareBank 1 Markets AS acted as managers for the Private Placement and are engaged as managers for the Subsequent Offering.

The company will receive gross proceeds of NOK 150 million ($17.4M) from the Private Placement when completed.

The company said it would use the net proceeds from the Private Placement for acquisition of a minority stake currently owned by Edvin Austbø (who is an indirect shareholder of Solon Eiendom) in a property project in Ski for approximately NOK60 million ($7M), acquisition of land for new projects and for general corporate purposes.

Leave a Reply

Please log in using one of these methods to post your comment: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s